Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis. J Med Econ • February 19, 2019
Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ • June 19, 2018
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the one-year EINSTEIN-Extension trial efficacy and safety results. J Med Econ • February 23, 2018
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for nonvalvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. J Med Econ • October 20, 2017
Cost and mortality impact of an algorithm-driven sepsis prediction system. J Med Econ • March 17, 2017
Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. J Med Econ • March 17, 2017
Impact of apixaban versus low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism. J Med Econ • November 9, 2016
Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism. J Med Econ • October 27, 2016July 29, 2017
The cost-effectiveness of exenatide twice daily (BID) versus insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. J Med Econ • June 30, 2016